COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA® for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older.
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older
Seeking Alpha / 1 hour from now 2 Views
Comments